FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celon Pharma's Free Cash Flow for the
three
months ended in Mar. 2026 was zł-19.2 Mil. Celon Pharma's Revenue for the
three
months ended in Mar. 2026 was zł56.9 Mil. Therefore, Celon Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was -33.77%.
The historical rank and industry rank for Celon Pharma's FCF Margin % or its related term are showing as below:
WAR:CLN'
s FCF Margin % Range Over the Past 10 Years
Min: -68.46 Med: -20.47 Max: 1.53
Current: -5.09
During the past 11 years, the highest FCF Margin % of Celon Pharma was 1.53%. The lowest was -68.46%. And the median was -20.47%.
WAR:CLN's FCF Margin % is ranked worse than 67.85% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs WAR:CLN: -5.09
Celon Pharma FCF Margin % Related Terms
Celon Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a FCF Margin % of -33.77% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #650 out of 958 companies in the Drug Manufacturers industry, placing it in the top 67.8%.
Is Celon Pharma's FCF Margin % too high?
Celon Pharma's current FCF Margin % is -33.77%. Based on the distribution chart, Celon Pharma ranks #650 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #650 out of 958 companies for FCF Margin %. This places Celon Pharma in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current FCF Margin % is -33.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.51, compared to a current price of zł19.52 — trading 13.3% below its estimated fair value. The current FCF Margin % is -33.77%. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current FCF Margin % is -33.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.52 is trading 13.3% below its estimated GF Value™ of zł22.51.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
FCF Margin %: -33.77%
GF Value™: zł22.51 vs. price of zł19.52 (13.3% below fair value)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score
Get the complete analysis for WAR:CLN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
